Free Trial
OTCMKTS:CHGCY

Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis

Chugai Pharmaceutical logo
$26.53 +0.22 (+0.84%)
As of 05/27/2025 04:00 PM Eastern

About Chugai Pharmaceutical Stock (OTCMKTS:CHGCY)

Key Stats

Today's Range
$26.04
$27.45
50-Day Range
$21.89
$30.18
52-Week Range
$14.52
$31.26
Volume
103,480 shs
Average Volume
198,412 shs
Market Capitalization
$87.31 billion
P/E Ratio
34.45
Dividend Yield
0.94%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Receive CHGCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chugai Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

CHGCY Stock News Headlines

Chugai Pharmaceutical Co., Ltd. (4519.T)
Trump Quietly Planning $15 Trillion Crypto Shocker
Most investors are still unaware, but I believe a new White House action may have quietly opened the floodgates for a $15 trillion crypto surge. My latest crypto playbook reveals the coin I’m most bullish on—including the name, ticker, and why I’m investing personal capital into it.
Jefferies Keeps Their Hold Rating on Chugai Pharmaceutical Co (CHGCF)
Bernstein Remains a Buy on Chugai Pharmaceutical Co (CHGCF)
See More Headlines

CHGCY Stock Analysis - Frequently Asked Questions

Chugai Pharmaceutical's stock was trading at $21.97 at the beginning of 2025. Since then, CHGCY shares have increased by 20.8% and is now trading at $26.53.
View the best growth stocks for 2025 here
.

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) announced its quarterly earnings data on Thursday, April, 24th. The company reported $0.19 EPS for the quarter. The business earned $1.89 billion during the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a trailing twelve-month return on equity of 21.53%.

Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/24/2025
Today
5/28/2025
Next Earnings (Estimated)
7/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Drugs, proprietaries, & sundries
Sub-Industry
N/A
Current Symbol
OTCMKTS:CHGCY
Fax
N/A
Employees
7,604
Year Founded
N/A

Profitability

Trailing P/E Ratio
34.45
Forward P/E Ratio
35.85
P/E Growth
N/A
Net Income
$2.56 billion
Pretax Margin
46.39%

Debt

Sales & Book Value

Annual Sales
$7.74 billion
Cash Flow
$0.91 per share
Price / Cash Flow
29.01
Book Value
$3.81 per share
Price / Book
6.96

Miscellaneous

Outstanding Shares
3,291,028,000
Free Float
N/A
Market Cap
$87.31 billion
Optionable
Not Optionable
Beta
0.76
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (OTCMKTS:CHGCY) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners